Navigation Links
Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
Date:11/10/2009

e information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genoptix Reports Strong Financial Results For Third Quarter 2007
2. Genoptix Announces Participation at the UBS Global Life Sciences Conference
3. Genoptix Announces Participation at the BIOCOM Investor Conference 2008
4. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
5. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
6. Genoptix Announces Participation at the 2009 Southern California Investor Conference
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The market for ... and is forecasted to reach $4B in 2015. , ... San Francisco, CA (PRWEB) June 28, 2010 -- In spite of ... digital brain health and fitness tools, grew 35% in 2009. “The convergence of ...
... Fla. , June 26 Orexigen® Therapeutics, Inc. (Nasdaq: ... demonstrating that treatment with Contrave® resulted in significant improvements in depressive ... eating in overweight and obese patients with major depression.   , ... The primary endpoint ...
... , June 25 Interleukin Genetics, Inc. (NYSE ... 24, 2010 , it received notification from the Corporate Compliance ... Exchange intends to initiate proceedings to delist the Company,s common ... of the Exchange,s Company Guide due to stockholders, equity of ...
Cached Biology Technology:New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 2New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 3New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 4New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 5Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 3Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 4Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 5Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex 2
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... between chronic cerebrospinal venous insufficiency (a reported condition ... drain blood from the brain and spinal cord ... sclerosis indicate that a minimally invasive endovascular treatment ... short-term improvement in physical- and mental health-related quality ...
... Cell therapy may present an option for patients with ischemic ... repair the damaged areas of their hearts, and may pave ... trial, which will be presented as a late-breaking clinical trial ... (ACC) scientific session. This is the largest study to ...
... New Rochelle, NY, March 21, 2012Healthy individuals who carry ... autism have structural differences in their brains that may ... increases vulnerability for autism. The results of this innovative ... the groundbreaking neuroscience journal Brain Connectivity, a ...
Cached Biology News:Interventional radiologists see 'significant' symptom relief in MS patients 2Interventional radiologists see 'significant' symptom relief in MS patients 3Cell therapy using patient's own bone marrow may present option for heart disease 2Cell therapy using patient's own bone marrow may present option for heart disease 3
... EPS 3501 XL Power Supply, 1. 3500 ... constant current, constant power, and linear voltage ... to focused equilibrium in IPG strips quickly ... compensate for variations in gel thickness, sample ...
...
Request Info...
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
Biology Products: